Reliance Global invests $2M in Innervate's late-stage radiopharmaceuticals for neuroblastoma imaging.

Reliance Global Group, through its biotech division LifeSci Global, invested approximately $2 million in Innervate Radiopharmaceuticals, a company developing advanced PET imaging agents for neuroblastoma, a serious pediatric cancer. This investment marks Reliance's entry into the late-stage radiopharmaceutical sector, targeting a $250 million initial market with potential expansion into cardiovascular and neurodegenerative diseases, each possibly exceeding $1 billion. Innervate's lead product, 18F-mFBG, aims to improve cancer imaging with higher resolution and faster scans compared to current standards. The investment aligns with Reliance's strategy to build exposure in high-growth healthcare platforms and could offer significant near-term and long-term value, including potential regulatory incentives like a Priority Review Voucher.